Table 4.

Association between serum adiponectin tertile and high PCS in clinically relevant subgroups.

	Adiponectin tertile
	T1	T2	T3	p for interaction
	OR (95% CI)	OR (95% CI)	OR (95% CI)
Sex				0.591
Female (n = 601)	1.25 [0.67–2.34]	1.40 [0.83–2.35]	Reference
Male (n = 950)	1.69 [1.07–2.68]	1.45 [0.93–2.28]	Reference
Age, years				0.678
< 55 (n = 820)	1.68 [1.03–2.73]	1.34 [0.85–2.11]	Reference
≥ 55 (n = 731)	1.38 [0.79–2.40]	1.59 [0.96–2.65]	Reference
BMI, kg/m2				0.564
< 23.5 (n = 605)	1.15 [0.65–2.04]	1.08 [0.67–1.76]	Reference
≥ 23.5 (n = 946)	1.96 [1.17–3.27]	1.81 [1.10–2.99]	Reference
Diabetes				0.532
Diabetes (−) (n = 1054)	1.80 [1.18–2.74]	1.66 [1.13–2.45]	Reference
Diabetes ( +) (n = 497)	1.11 [0.55–2.26]	0.87 [0.43–1.76]	Reference
eGFR, mL/min/1.73 m2				0.029
< 45 (n = 734)	2.73 [1.54–4.85]	2.22 [1.30–3.79]	Reference
≥ 45 (n = 817)	1.02 [0.64–1.64]	1.04 [0.67–1.63]	Reference
Urine protein/creatinine, g/g				0.925
< 1.0 (n = 1039)	1.74 [1.12–2.70]	1.50 [0.99–2.26]	Reference
≥ 1.0 (n = 512)	1.28 [0.66–2.46]	1.23 [0.67–2.26]	Reference
CRP, mg/dL				0.452
< 0.5 (n = 632)	1.50 [0.87–2.60]	1.22 [0.75–1.98]	Reference
≥ 0.5 (n = 919)	1.56 [0.95–2.56]	1.60 [0.99–2.58]	Reference

BMI body mass index; eGFR estimated glomerular filtration rate; CRP C-reactive protein.